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Abstract
Background: Gallbladder cancer (GBC) is likely to be diagnosed at progressive stages and shows a very poor
prognosis. Combination therapy with gemcitabine and cisplatin (GEMCIS) has been widely used as first-line
palliative chemotherapy for advanced GBC. This study was designed to investigate the efficacy of GEMCIS and
identify prognostic factors in patients with unresectable GBC.
Methods: Patients with GBC who were treated with GEMCIS from January 2008 to June 2017 in a single tertiary
hospital were included. All cases of GBC were diagnosed by pathologic findings and extent of the tumour was
assessed by imaging tests. Combination chemotherapy consisted of cisplatin 25mg/m2 and gemcitabine 1000mg/m2
intravenously on days 1 and 8 every 3 weeks. To determine factors affecting prognosis, Kaplan–Meier survival analysis,
log-rank test and the Cox proportional hazard regression linear model were used. All variables with P < 0.1 in
univariable analysis were included in the multivariable model.
Results: A total of 173 patients received a median of 5.3 ± 4.4 cycles of chemotherapy over 3.8 ± 3.9 months. Most of
the patients (94.8%) were stage IVB at the time of diagnosis and the most common site of metastasis was the liver (42.
8%). Disease control rate was 59.5%: 2 (1.2%) patients with complete response, 26 (15.0%) patients with partial response
and 75 (43.4%) patients with stable disease. Overall survival (OS) and progression-free survival were 8.1 (95% confidence
interval [CI], 7.1–10.2) and 5.6 (95% CI 4.5–6.8) months, respectively. Multivariable regression model indicated that
metastasis to liver (hazard ratio [HR] = 1.63, 95% CI 1.11–2.40; P = 0.013), neutrophil-to-lymphocyte ratio (NLR) ≥3 (HR 1.
65, 95% CI 1.09–2.49; P = 0.017), CEA≥ 5 ng/mL (HR 1.50, 95% CI 1.02–2.19; P = 0.038), and CA19–9≥ 500 U/mL (HR 1.59,
95% CI 1.01–2.50; P = 0.043) were significantly associated with OS.
Conclusions: GEMCIS demonstrated a high disease control rate in patients with unresectable GBC. Factors
independently related to OS were metastasis to liver, NLR≥ 3, CEA≥ 5 ng/mL and CA19–9≥ 500 U/mL.
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Background
Gallbladder cancer (GBC) accounts for 80 to 90% of
carcinomas in the biliary system. Cancer-related mor-
tality among patients with GBC is increasing and ex-
pected to continue to increase until 2030 worldwide
[1]. Since there are no specific symptoms in the early
stage, GBC is often not diagnosed until advanced
stages. Surgery is the only curative treatment method;
however, fewer than 10% of patients can undergo sur-
gery, and 50% are found to have metastasis to lymph
nodes at the time of diagnosis [2]. GBC has an abysmal
prognosis and a median survival of 6 months if
untreated [3].
Gemcitabine plus cisplatin (GEMCIS) is widely used
as first-line chemotherapy for unresectable GBC based
on a recent clinical trial showing favourable outcomes
of the combination chemotherapy in patients with bil-
iary tract cancer (BTC) [4]. Median overall survival
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(OS) and progression-free survival (PFS) were 11.7 and
8.0 months, respectively, in patients with BTC treated
with GEMCIS [4]. However, in a more recent phase II
clinical study that included only patients with unresect-
able GBC, median OS and PFS were 6.2 and 3.1
months, respectively [5]. Another study revealed that
gallbladder cancer responds poorly to chemotherapy
compared to other subtypes of biliary tract cancer [6].
Even though prognosis and response to chemotherapy
in patients with GBC are different from those in pa-
tients with other subtypes of BTC, there is a lack of
studies evaluating the efficacy of GEMCIS only in pa-
tients with GBC.
Several studies have identified various prognostic fac-
tors in patients with GBC, including jaundice, metastasis
to lymph nodes, and metastasis to liver [7–10]. Tumour
markers, particularly carcinoembryonic antigen (CEA)
and carbohydrate antigen 19–9 (CA19–9), are also
well-known prognostic factors in GBC [11–13]. In addition,
it has been shown that several variables of systemic inflam-
mation response such as neutrophil-to-lymphocyte ratio
(NLR) and platelet-to-lymphocyte ratio (PLR) have prog-
nostic value in BTC [14–16]. However, previous studies are
based on retrospective data from patients with BTC or
GBC who were treated surgically, and prognostic factors in
patients with unresectable GBC treated with GEMCIS are
largely unknown.
Although GEMCIS is widely used in patients with
advanced GBC based on the clinical trial in 2010,
there may be differences in treatment efficacy be-
tween GBC and other subtypes of BTC. Moreover,
previous studies regarding treatment efficacy and
prognostic factors have focused mainly on patients
with BTC or GBC who were treated primarily by sur-
gery. Therefore, this study aimed to evaluate the effi-
cacy of GEMCIS and identify prognostic factors in
only patients with unresectable GBC.
Methods
Study subjects
Patients with unresectable GBC who were treated with
GEMCIS at Seoul National University Hospital between
January 2008 and June 2017 were analysed. All patients
were diagnosed by pathologic confirmation and medical
records of the patients were retrospectively reviewed. Ex-
tent of the disease was evaluated by contrast-enhanced
computed tomography and 18F-fluoro-2-deoxy-D-glucose
positron emission tomography with computed tomog-
raphy scan.
Locations of regional lymph nodes included hepatic
hilus along the common bile duct, hepatic artery, portal
vein, and cystic duct, whereas involvement of lymph
nodes around the celiac and superior mesenteric artery
was considered distant metastatic disease [17]. A total
of 186 patients were reviewed. Five patients who lacked
baseline laboratory findings and eight patients with his-
tory of active cancer in another organ within 5 years
were excluded (Fig. 1). In total, 173 patients were en-
rolled and analysed. This study was approved by the In-
stitutional Review Board of the Seoul National
University Hospital, Seoul, Korea (1703–004-834).
Treatment and data collection
Each cycle of combination chemotherapy consisted of
cisplatin 25mg/m2 and gemcitabine 1000 mg/m2 admin-
istered intravenously on days 1 and 8 every 3 weeks. The
treatment was repeated until the occurrence of un-
acceptable toxicity, loss to follow-up, confirmation of
disease progression, or death. Patients were followed up
regularly and laboratory tests and imaging tests were
periodically evaluated to assess therapeutic outcomes.
Demographic and clinical variables included age,
gender, Eastern Cooperative Oncology Group (ECOG)
performance status, body mass index, Charlson comor-
bidity index score, cancer stage, location of invasion
and metastasis, previous therapeutic history, and total
number of chemotherapy cycles. Laboratory variables
included glomerular filtration rate, aspartate amino-
transferase, alanine aminotransferase, total bilirubin,
alkaline phosphatase, CEA, CA19–9, NLR, and PLR.
NLR and PLR values were defined as the number of
absolute neutrophils and platelets divided by the abso-
lute lymphocyte count from samples of peripheral
blood, respectively.
The primary endpoint was OS and the secondary
endpoints were PFS and objective best overall tumour
response. OS was defined as time from initiation of
chemotherapy to the final date of follow-up or death
from any cause. PFS was defined as time from initial
treatment to the confirmation of disease progression or
death. Mortality data were collected by the Ministry of
the Interior and Safety. Best overall tumour response
was assessed by contrast-enhanced CT scan based on
the Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1 criteria [18]. Minimum duration for def-
inition of stable disease was 1 month and tumour re-
sponse was evaluated at intervals of two cycles.
Statistical analysis
Continuous variables with a normal distribution were
expressed as the mean and standard deviation, while
those with a non-normal distribution were summarised
as the median and interquartile range (IQR). Categor-
ical variables were presented with percentage, and the
Pearson χ2 test was applied to determine differences be-
tween them. OS and PFS were calculated and compared
using the Kaplan–Meier method and the log-rank test.
To determine factors affecting prognosis, hazard ratio
You et al. BMC Cancer           (2019) 19:10 Page 2 of 10
(HR) and 95% confidence interval (CI) for OS and PFS
were calculated using the Cox’s proportional hazard re-
gression model. Best cut-off values of NLR, PLR, and
tumour markers were obtained using the Contal and
O’Quigley method [19]. Multivariable analysis was per-
formed including variables with P < 0.1 in univariable ana-
lysis. Variables with P < 0.05 were considered to indicate
statistical significance. All statistical analyses were per-
formed using R ver. 3.3.3 (Institute for Statistics and
Mathematics, Vienna, Austria; http://www.R-project.org).
Results
Clinical characteristics of patients
Baseline characteristics are summarised in Table 1.
The most common site of adjacent cancer invasion
was the liver (27.2%), followed by the extrahepatic bile
duct (15.0%) and intestine (11.6%). Invasion of hepatic
artery and main portal vein was identified in 15 (8.7%)
and 11 (6.4%) patients, respectively. Twenty-seven
(15.6%) patients were identified to have invasion to
more than two organs. Most of the patients (94.8%)
were in stage IVB. Among the total patients, liver me-
tastasis was identified in 74 (42.8%) patients, followed
by peritoneum in 46 (26.6%) and lung in 29 (16.8%)
patients. There were two patients each with metastasis
to abdominal wall and adrenal gland and one patient
with metastasis to spleen. Metastasis to distant lymph
node was found in 102 (59.0%) patients, pericaval area
in 58 (33.6%), paraaortic area in 65 (37.6%), and the
area above the diaphragm in 31 (17.9%) patients.
Eighty-one (46.8%) patients had metastasis to multiple
lymph nodes.
Previous history of curative surgery was identified in
33 (19.1%) patients, extended cholecystectomy in 23
(69.7%), and simple cholecystectomy in 10 (30.3%) pa-
tients. Median duration after surgery until recurrence
Fig. 1 Flow chart of patient enrolment between January 2008 and June 2017. GBC, gallbladder cancer; GEMCIS, gemcitabine plus cisplatin
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was 10.0 (95% CI 7.79–16.34) months. Median OS in pa-
tients with previous history of curative surgery and those
without was 7.8 (95% CI 6.7–10.0) and 11.1 (95% CI 6.7–
15.1) months, respectively (P = 0.202). Twelve patients
had previous history of palliative chemotherapy; nine
patients received fluoropyrimidine-based chemotherapy,
and the other three patients had palliative concurrent che-
moradiation therapy with fluoropyrimidine. Among 44
(25.4%) patients who underwent biliary drainage due to
malignant hilar obstruction before the initial chemother-
apy, 35 (79.5%) were treated with endoscopic retrograde
biliary drainage and 9 (20.5%) with percutaneous transhe-
patic biliary drainage.
Treatment outcomes
Treatment data during GEMCIS chemotherapy are
summarised in Table 2. The median follow-up duration
was 8.6 ± 7.1 months. Based on 147 (85.0%) deaths, OS
was 8.1 (95% CI 7.1–10.2) and PFS was 5.6 (95% CI
4.5–6.8) months (Fig. 2). Disease control was achieved
in 103 (59.5%) patients; 2 (1.2%) with complete re-
sponse (CR), 26 (15.0%) with partial response, and 75
(43.4%) with stable disease. Of the two patients with
the best CR response, one patient who initially had me-
tastasis to peritoneum remained in CR until the last
Table 1 Baseline characteristics of all patients
Variables N = 173
Age (range) 63.8 (25.0–84.0)
Sex (female / male) 86 (49.7%) / 87 (50.3%)
ECOG (0 / 1 / 2) 36 (20.8%) / 126
(72.8%) / 11 (6.4%)
BMI 23.0 ± 2.8
Charlson comorbidity index 8.0 ± 1.4
Stage (IIIB / IVA / IVB) 1 (0.6%) / 8
(4.6%) / 164 (94.8%)
Invasion
Liver 47 (27.2%)
Extrahepatic bile duct 26 (15.0%)
Intestine 20 (11.6%)
Peritoneum 2 (1.2%)
Hepatic artery 15 (8.7%)





Bone or muscular system 14 (8.1%)
Distant lymph node 102 (59.0%)
Previous history
Biliary drainage 49 (28.3%)
Curative surgery 33 (19.1%)
Palliative chemotherapy 12 (8.5%)
Baseline laboratory findings
WBC (cells/μL) 6540.0 ± 5192.4
CRP (mg/dL) 3.5 ± 4.0
eGFR (mL/min/1.73m2) 92.8 ± 23.1
AST (IU/L) 40.3 ± 40.3
ALT (IU/L) 44.2 ± 50.8
ALP (IU/L) 183.7 ± 174.9
Bilirubin, total (mg/dL) 1.5 ± 2.4
CEA (ng/mL) 68.6 ± 247.7
CA 19–9 (U/mL) 2676.9 ± 6783.1
NLR 4.2 ± 3.4
PLR 189.0 ± 95.0
ECOG Eastern Cooperative Oncology Group, BMI body mass index, WBC white
blood cell, CRP C-reactive protein, eGFR estimated glomerluar filtration rate,
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline
phosphatase, CEA carcinoembryonic antigen, CA 19–9 carbohydrate antigen
19–9, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
Table 2 Treatment data and efficacy of GEMCIS in unresectable
gallbladder cancer
Variables N = 173
Treatment duration, months 3.8 ± 3.9
Total cycle 5.3 ± 4.4
OS, months (95% CI) 8.1 (7.1–10.2)







ORR (CR + PR) 28 (16.2%)











≥ 10 30 (17.4%)
GEMCIS gemcitabine plus cisplatin, OS overall survival, PFS progression-free
survival, CI confidence interval, CR complete response, PR partial response, SD
stable disease, PD progressive disease, NE not evaluable, ORR overall response
rate, DCR disease control rate
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date of follow-up and the other patient showed pro-
gression of disease with recurrence at the lung 10
months after the last chemotherapy.
Patients received a total of 5.3 ± 4.4 cycles of chemother-
apy during 3.8 ± 3.9 months. A subsequent line of
chemotherapy was feasible in 73 (42.2%) patients:
fluoropyrimidine-based therapy in 57 (32.9%), clinical trial
in 14 (8.1%), gemcitabine single therapy in 2 (1.5%), and
concurrent chemoradiation therapy with fluoropyrimidine
in 1 (0.7%) patient. Median overall survival of the patients
who underwent further lines of palliative chemotherapy
was 10.2 (95% CI 8.1–12.0) months, which was not signifi-
cantly different from that of patients who did not receive a
subsequent line of chemotherapy (median OS 6.4months;
95% CI 4.4–9.7; P = 0.086).
With regard to hematological grade 3/4 toxicity, neutro-
paenia was most commonly noted (28.6%), followed by
anaemia (19.3%) and thrombocytopaenia (17.1%). Febrile
neutropaenia occurred in eight patients (4.6%). Deep vein
thrombosis and pulmonary thromboembolism developed
in 18 (10.4%) and 9 (5.2%) patients, respectively. Trans-
aminase increased to more than 3 times the upper limits
of normal in 27 (15.6%) patients during treatment. Nausea
and/or vomiting (20.2%) and diarrhoea (6.9%) frequently
occurred. Severe non-haematological toxicity of grade 3
or greater was infrequent and included diarrhoea (n = 3),
nausea/vomiting (n = 2), and neuropathy (n = 1).
Prognostic factors
In univariable analysis, several variables showed P < 0.1
(Table 3): ECOG 2 (HR 1.86; 95% CI 0.94–3.68; P = 0.074),
invasion to liver (HR 1.47; 95% CI 1.02–2.12; P = 0.040),
metastasis to liver (HR 1.72; 95% CI 1.23–2.41; P = 0.002),
metastasis to bone and muscle (HR 2.03; 95% CI 1.14–
3.61; P = 0.016), total bilirubin≥1.5 X upper limit of nor-
mal (HR 1.77; 95% CI 1.21–2.58; P = 0.003), transamin-
ase≥1.5 X upper limit of normal (HR 1.53; 95% CI
1.07–2.18; P = 0.019), NLR ≥ 3 (HR 2.34; 95% CI 1.66–
3.29; P < 0.001), PLR ≥ 190 (HR 1.77; 95% CI 1.27–2.47;
P < 0.001), CEA ≥ 5 ng/mL (HR 1.87; 95% CI 1.33–2.63;
P < 0.001), and CA 19–9 ≥ 500 U/mL (HR 2.28; 95% CI
1.61–3.23; P < 0.001).
The results of multivariable analysis are listed in
Table 4. In the final multivariable analysis, independent
prognostic factors for poor OS were metastasis to liver
(HR 1.63; 95% CI 1.11–2.40; P = 0.013), NLR ≥ 3 (HR
1.65; 95% CI 1.09–2.49; P = 0.017), CEA ≥ 5 ng/mL (HR
1.50; 95% CI 1.02–2.19; P = 0.038) and CA19–9 ≥ 500
(HR 1.59; 95% CI 1.01–2.50; P = 0.043). Median OS in
patients with liver metastasis was 6.2 (95% CI 5.3–10.0,
P = 0.001) months (Fig. 3). Hypertransaminasemia was
identified in 26/74 (35.1%) patients in patients with liver
metastasis, which was not significantly different from the
incidence in patients without liver metastasis (P = 0.346).
When classified by baseline NLR ≥ 3, CA 19–9 ≥ 500 U/
mL and CEA ≥ 5 ng/mL, median OS was 6.2 (95% CI 4.8–
7.8, P < 0.001), 5.5 (95% CI 4.1–7.6, P < 0.001) and 6.5
(95% CI 5.0–8.1, P < 0.001) months, respectively (Fig. 4).
Discussion
The aim of this study was to examine the efficacy of
GEMCIS and identify prognostic factors in unresectable
GBC. In this study, GEMCIS showed a high disease
control rate, and liver metastasis, NLR, CEA, and CA
19–9 were significantly associated with prognosis.
Overall, this study showed a median OS of 8.6 months,
Fig. 2 Overall survival (OS) and progression-free survival (PFS) of patients treated with gemcitabine plus cisplatin
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Table 3 Univariable analysis of possible factors affecting overall survival
Number of patients (%) Median OS, months (95% CI) HR (95% CI) P value
Age
< 65 90 (52.0%) 10.1 (7.6–11.4) 1.00
≥ 65 83 (48.0%) 7.2 (6.0–10.0) 1.28 (0.92–1.78) 0.138
Sex (female/ male)
Female 86 (49.7%) 10.1 (7.8–12) 1.00
Male 87 (50.3%) 7.1 (5.5–10.1) 1.22 (0.88–1.69) 0.234
ECOG
0–1 164 (94.8%) 8.1 (7.1–10.3) 1.00
2 9 (5.2%) 7.5 (2.8-NE) 1.86 (0.94–3.68) 0.074
BMI
> 25 136 (78.6%) 7.8 (6.6–9.7) 1.00
≥ 25 37 (21.4%) 11.9 (7.1–15.1) 0.79 (0.53–1.18) 0.255
Stage
IIIB/ IVA 9 (5.2%) 7.2 (2.1-NE) 1.00
IVB 164 (94.8%) 8.1 (7.1–10.3) 0.68 (0.35–1.35) 0.272
Charlson comorbidity index
< 9 110 (63.6%) 9.7 (7.8–11.0) 1.00
≥ 9 63 (36.4%) 6.4 (4.4–10.2) 1.23 (0.87–1.72) 0.237
Local invasion
Liver 47 (27.2%) 7.7 (6.6–11.4) 1.47 (1.02–2.12) 0.040
Extrahepatic bile duct 26 (15.0%) 6.5 (5.0–11.9) 1.06 (0.67–1.67) 0.812
Intestine 20 (11.6%) 8.6 (5.0-NE) 0.79 (0.47–1.34) 0.386
Peritoneum 2 (1.2%) 10.5 (2.3-NE) 0.94 (0.23–3.82) 0.933
Hepatic artery 15 (8.7%) 6.4 (5.0-NE) 1.12 (0.63–1.98) 0.699
Portal vein 11 (6.4%) 5.9 (2.3-NE) 1.17 (0.6–2.31) 0.643
Metastasis site
Liver 74 (42.8%) 6.2 (5.3–10.0) 1.72 (1.23–2.41) 0.002
Peritoneum 46 (26.6%) 6.5 (4.2–10.1) 1.25 (0.87–1.82) 0.229
Lung 29 (16.8%) 7.2 (5.4–15.6) 0.85 (0.54–1.34) 0.487
Bone or muscular system 14 (8.1%) 5.1 (3.3–13.1) 2.03 (1.14–3.61) 0.016
Distant lymph node 102 (59.0%) 8.3 (6.5–10.9) 1.10 (0.79–1.54) 0.560
Total bilirubin
≤ 1.5 X ULN 130 (75.1%) 9.7 (7.8–11.0) 1.00
> 1.5 X ULN 43 (24.9%) 5.3 (3.7–9.5) 1.77 (1.21–2.58) 0.003
Transaminase
≤ 1.5 X ULN 120 (69.4%) 9.7 (7.8–11.5) 1.00
> 1.5 X ULN 53 (30.6%) 6.2 (4.5–9.7) 1.53 (1.07–2.18) 0.019
NLR
≤ 3 75 (43.4%) 12.4 (10.2–14.6) 1.00
> 3 98 (56.6%) 6.2 (4.8–7.8) 2.34 (1.66–3.29) < 0.001
PLR
< 190 102 (59.0%) 10.3 (9.4–13.7) 1.00
≥ 190 71 (41.0%) 6.6 (5.6–8.1) 1.77 (1.27–2.47) 0.001
CEA, ng/mL
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in general accordance with the previous phase II study
in Japan regarding the efficacy of GEMCIS in 14 pa-
tients with unresectable GBC [4]. On the other hand,
previous study which investigated efficacy of GEMCIS
in patients with BTC reported the median OS of 11.7
months, suggesting that prognosis is worse in GBC
than that in other subtypes of BTC [4, 5]. Moreover, in
this study, there were 76 patients who were not able to
undergo chemotherapy, 48 patients loss to follow-up,
and 4 patients who died immediately after GBC diagno-
sis. Since GEMCIS was clinically applied in patients
with generally good performance, the actual prognosis
of unresectable GBC is likely to be worse than the
prognosis reported in this study.
The gallbladder has no serosal layer near the liver
and its perimuscular connective tissue is in direct con-
tact with the liver. Subsequently, invasion of GBC into
liver is very common and liver involvement is known to
be associated with poor prognosis [3, 6]. In this study,
however, liver invasion was not an independent prog-
nostic factor, as opposed to previous studies which
mostly included patients with resectable GBC. The dis-
crepancy may stem from the different inclusion criteria.
Meanwhile, metastasis to liver, which occurs via portal
tracts, is common in advanced GBC and indicates poor
prognosis [9, 20, 21]. These findings coincide well with
the results of our study that identified liver metastasis
as an independent poor prognostic factor. Currently,
there are no standard treatment methods regarding
liver metastasis although several chemotherapy regi-
mens can be considered in patients with liver metasta-
sis on the basis of the National Comprehensive Cancer
Network Clinical Practice Guidelines [22]. Because of
the absence of the specific standard treatment guide-
lines, further studies are required to evaluate best treat-
ment modalities for liver metastasis.
It is well known that CEA and CA19–9 are helpful
not only in diagnosis, but also in predicting prognosis
of GBC [11, 12]. Wang et al. [13] reported that CA19–
9 plays an important role as an independent prognostic
factor in GBC. Likewise, Park et al. [23] recently re-
ported that CEA independently predicts prognosis in
patients with metastatic BTC. Consistent with previous
Table 3 Univariable analysis of possible factors affecting overall survival (Continued)
Number of patients (%) Median OS, months (95% CI) HR (95% CI) P value
< 5 103 (59.5%) 10.3 (7.8–13.1) 1.00
≥ 5 70 (40.5%) 6.5 (5.0–8.1) 1.87 (1.33–2.63) < 0.001
CA 19–9, U/mL
< 500 114 (65.9%) 10.7 (9.0–13.3) 1.00
≥ 500 59 (34.1%) 5.5 (4.1–7.6) 2.28 (1.61–3.23) < 0.001
OS overall survival, HR hazard ratio, ECOG Eastern Cooperative Oncology Group, BMI body mass index, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-
lymphocyte ratio, CEA carcinoembryonic antigen, CA 19–9 carbohydrate antigen 19–9, NE not estimable, ULN upper limit of normal
Table 4 Multivariable analysis by Cox regression model
Variable Number HR (95% CI) P-value
ECOG
0–1 164 1.00
2 9 0.79 (0.34–1.85) 0.586
Invasion to liver
No 126 1.00
Yes 47 0.91 (0.59–1.39) 0.648
Metastasis to liver
No 99 1.00
Yes 74 1.63 (1.11–2.40) 0.013
Metastasis to bone and muscle
No 159 1.00
Yes 14 1.78 (0.93–3.42) 0.081
NLR
< 3 75 1.00
≥ 3 98 1.65 (1.09–2.49) 0.017
PLR
< 190 102 1.00
≥ 190 71 1.19 (0.79–1.77) 0.405
Total bilirubin
≤ 1.5 X ULN 130 1.00
> 1.5 X ULN 43 1.56 (0.95–2.55) 0.077
Transaminase
≤ 1.5 X ULN 120 1.00
> 1.5 X ULN 53 0.92 (0.59–1.45) 0.723
CEA, ng/mL
< 5 103 1.00
≥ 5 70 1.50 (1.02–2.19) 0.038
CA 19–9, U/mL
< 500 114 1.00
≥ 500 59 1.59 (1.01–2.50) 0.043
ECOG Eastern Cooperative Oncology Group, CEA carcinoembryonic antigen, CA
19–9 carbohydrate antigen 19–9, NLR neutrophil-to-lymphocyte ratio, PLR
platelet-to-lymphocyte ratio, CEA carcinoembryonic antigen, CA 19–9
carbohydrate antigen 19–9, ULN upper limit of normal
You et al. BMC Cancer           (2019) 19:10 Page 7 of 10
studies [23, 24], the results of our study demonstrated
that baseline CA 19–9 and CEA level were independent
prognostic markers.
The association of NLR with prognosis has been widely
studied in patients with BTC [15, 16, 23, 25]. Zhang et al.
[14] found that patients with NLR ≥ 2.61 had a worse
prognosis than those with NLR < 2.61 in a study of 316
patients with GBC treated with surgery. In our study,
multivariate analysis revealed NLR ≥ 3 as an independent
risk factor for poor OS, which was in general accordance
with previous studies. The correlation between NLR and
prognosis can be explained by the fact that neutrophils se-
crete vascular endothelial growth factors and several cyto-
kines to promote tumour development and proliferation
whereas lymphocytes play a crucial role in tumour defence
by inducing cytotoxic cell death [26–28].
Fig. 3 Kaplan–Meier curves of overall survival according to liver metastasis
Fig. 4 Kaplan–Meier curves of overall survival according to groups based on the results of multivariable analysis and log-rank test. a Classified by
NLR ≥3. b Classified by CA19–9 ≥ 500 U/mL and CEA≥ 5 ng/mL. NLR, neutrophil-to-lymphocyte ratio; CA 19–9, carbohydrate antigen 19–9; CEA,
carcinoembryonic antigen
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Pro-inflammatory and pro-angiogenic cytokines are
known to be important causative factors in the develop-
ment of BTC and cytokine-based therapies have been
studied [29]. It is expected that the NLR will play an im-
portant role in the prediction of prognosis in future devel-
opment of therapies targeting cancer-associated
inflammation.
A limitation of our study is that it is based on retro-
spective data from a single tertiary care center. Al-
though the results of our study showed a somewhat
longer OS than the previous phase II clinical trial in
Japan, there may be several confounding factors stem-
ming from the retrospective study design that affect the
results of analysis. Second, since the present study was
conducted without a control group, careful interpret-
ation and further validation is needed. Despite these
limitations, clinical data from this study are helpful be-
cause there are very few studies examining the efficacy
of GEMCIS combination chemotherapy and prognostic
factors specifically in patients with unresectable GBC.
Third, the cut-off values of the tumour markers,
NLR, and PLR were estimated based on a relatively
small sample size. Although these cut-off values were
found to be statistically significant, a large-scale pro-
spective study to determine the ideal cut-off value is
needed. Another limitation is that direct invasion of
GBC to surrounding tissues was based on imaging find-
ings because we selected only patients with unresect-
able disease. Diagnostic aspects of imaging tests in
evaluating direct invasion of tumour to surrounding tis-
sues may be less sensitive or less accurate than patho-
logic examination accompanied by surgical resection.
Nevertheless, due to the development of recent imaging
techniques, the sensitivity and specificity of the diagno-
sis by computed tomography are as high as 99 and 76%,
respectively, and the interpretation of the results of this
study seems to be reasonable [30].
Conclusions
In conclusion, GEMCIS is an effective regimen in pa-
tients with unresectable GBC. The prognostic factors
identified in this study might help accurate patient risk
stratification and decision of a proper treatment plan.
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